Loading
Luminary Therapeutics
Luminary Therapeutics is a Minneapolis company making CAR-T cells, immune cells engineered to find cancer, that use the natural BAFF ligand to hit three receptors on B cells at once. Its first product, LMY-920, is in early trials in lymphoma, myeloma and leukaemia.
Also called: Luminary Therapeutics, Inc.
Overview
Luminary Therapeutics describes itself as a clinical-stage company developing allogeneic cell therapies, with a gamma-delta T cell platform intended to yield many doses from one donor. Its BAFF-L CAR binds three receptors across the B-cell lineage. The lead product LMY-920, an alpha-beta T cell BAFF-L CAR, is listed on its pipeline page in non-Hodgkin lymphoma (NCT05312801, Cleveland Clinic), multiple myeloma (NCT05546723, University Hospitals) and chronic lymphocytic leukaemia, alongside an autoimmune trial. In fiscal year 2026 NCI awarded it USD 586,799 under SBIR award 5R44CA278021-03 for allogeneic BAFF ligand-based CAR-T cells in B-cell malignancies.
Headquarters
Minneapolis, MN, US
Scorecard
All companies#726of 1706 companies, score 3
- phase 1/2 +1
- modalities +2
0 approved, 0 in phase 3, 1 earlier, 0 targets, 0 registry studies. Formula on the scorecards page.
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI SBIR award (R44) 5R44CA278021-03: Allogeneic BAFF Ligand Based CAR T Cells as a Novel Therapy for B Cell Malignancies | 2026 | $587K | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Products
1Phase 1Autologous CAR-T cell therapy (BAFF ligand-based CAR)
LMY-920 is an experimental CAR-T treatment from Luminary Therapeutics, made from a patient's own immune cells, aimed at three receptors on cancerous B cells. It is in early trials in lymphoma and myeloma.
Notes
- Patient numbers on the pipeline page are the company's own. Read on luminarytx.com, ClinicalTrials.gov and NIH RePORTER on 4 November 2026.
Connected
6Similar pages
- CompanyCARTx Therapeutics
- CompanyEver Supreme Bio Technology
Shares Gamma-delta T cell therapy, Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy.
- CompanyEdiGene
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy.
- CompanyImugene
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy.
- CompanyTikva Allocell
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy.
- PersonStephen J. Forman
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy.
- CompanyAllotera Therapeutics (formerly Wugen)
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy.
- CompanyAdicet Bio
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy.
fronts
technologies
drugs
Phase 1Autologous CAR-T cell therapy (BAFF ligand-based CAR)
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
luminarytx.com · 2
nih.gov · 1
A source that has moved or gone is reported by the weekly link check. /audit/